News
Amgen Inc. (NASDAQ:AMGN)’s thrombocytopenia drug Nplate (romiplostim) showed significant benefits in a Phase III trial for ...
Clinical Trials Arena on MSN5d
ASCO25: Amgen’s Nplate proves effective in GI cancer-linked thrombocytopaeniaNplate improved platelet response and reduced therapy modification for patients with chemotherapy-induced thrombocytopaenia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback